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Risk of neural tube defects (NTDs) is determined by genetic and environmental factors, among which folate
status appears to play a key role. However, the precise nature of the link between low folate status and NTDs
is poorly understood, and it remains unclear how folic acid prevents NTDs. We investigated the effect of
folate level on risk of NTDs in splotch (Sp2H) mice, which carry a mutation in Pax3. Dietary folate restriction
results in reduced maternal blood folate, elevated plasma homocysteine and reduced embryonic folate con-
tent. Folate deficiency does not cause NTDs in wild-type mice, but causes a significant increase in cranial
NTDs among Sp2H embryos, demonstrating a gene–environment interaction. Control treatments, in which
intermediate levels of folate are supplied, suggest that NTD risk is related to embryonic folate concentration,
not maternal blood folate concentration. Notably, the effect of folate deficiency appears more deleterious in
female embryos than males, since defects are not prevented by exogenous folic acid. Folate-deficient
embryos exhibit developmental delay and growth retardation. However, folate content normalized to protein
content is appropriate for developmental stage, suggesting that folate availability places a tight limit on
growth and development. Folate-deficient embryos also exhibit a reduced ratio of s-adenosylmethionine
(SAM) to s-adenosylhomocysteine (SAH). This could indicate inhibition of the methylation cycle, but we
did not detect any diminution in global DNA methylation, in contrast to embryos in which the methylation
cycle was specifically inhibited. Hence, folate deficiency increases the risk of NTDs in genetically predis-
posed splotch embryos, probably via embryonic growth retardation.
INTRODUCTION
Neural tube defects (NTDs), including spina bifida and
anencephaly, are among the commonest human birth defects,
affecting around 1 in every 1000 pregnancies. While the
causes of human NTDs remain poorly understood in most
cases (1–3), more than 100 single-gene defects can cause
NTDs in mouse models. Nevertheless, the existence of many
gene–gene and gene–environment interactions in the aetio-
logy of mouse NTDs, and analysis of inheritance patterns in
humans, argues strongly for a multi-factorial model in
humans, in which susceptibility to NTDs is determined
by multiple genetic and environmental factors (4–6).
Among environmental factors, folate status appears to be a
key determinant of NTD susceptibility since maternal sup-
plementation with folic acid during early pregnancy reduces
the risk of NTDs in the developing fetus (7–9). Conversely,
reduced serum folate levels and/or elevated homocysteine
levels (an inverse indicator of folate status) are observed in
some mothers with NTD fetuses, and are considered risk
factors for NTDs (10,11).
Despite compelling evidence that supplemental folic acid
can prevent many cases of NTDs, neither the protective mech-
anism nor the relationship between maternal folate status and
susceptibility to NTDs are well-defined. Moreover, some
NTDs are not preventable by folic acid (12,13). NTDs do
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not appear to result simply from maternal folate deficiency,
which is corrected by folic acid supplementation, since
maternal folate levels in most affected pregnancies are
within the ‘normal’ range (9,10). In order to investigate the
role of sub-optimal folate status in causation of NTDs,
studies in mice have made use of modified diets to induce
severe folate deficiency in dams prior to mating. This results
in reduced fetal weight, developmental delay and increased
resorption rate among the offspring (14,15), although NTDs
are not observed, arguing against a role for folate deficiency
as a sole causative factor. Direct disruption of cellular folate
uptake, by genetic ablation of folate-binding protein (Folr1),
results in lethality in null embryos (16). In vivo supplemen-
tation with folinic acid (or 5-methyltetrahydrofolate) allows
survival beyond neurulation stages, and a proportion of the
embryos exhibit NTDs, suggesting that folate availability is
important for neural tube closure (17).
The relatively mild reduction in folate status among human
NTDs and the lack of induction of NTDs by dietary folate
deficiency in animal models could be interpreted to indicate
that low folate status is, at most, a minor contributory factor
in determining susceptibility to NTDs. However, in some
studies a dose–response relationship between maternal folate
status and NTD risk has been noted (18). Thus, it has been
proposed that low folate status may increase susceptibility to
NTDs when present in combination with another environmental
or genetic risk factor (5,13). Although this is an attractive and
frequently cited hypothesis, a causative interaction between
low folate status and genetic predisposition has not been
demonstrated to date. Mammals cannot synthesize folates
de novo, and intestinal absorption is therefore required to obtain
this essential micronutrient from exogenous sources (19).
Dietary folates are converted from polyglutamated forms to
monoglutamates and preferentially absorbed in the small intes-
tine. In addition, the bacterial microflora of the large intestine
provide a second source of folates (20). In this study, we tested
the hypothesis that dietary folate deficiency may increase risk
of NTDs in genetically predisposed embryos, using the mutant
mouse model, splotch (Sp2H), which carries an intragenic dele-
tion in the Pax3 gene. Homozygous Sp2H mutant embryos
exhibit both cranial (exencephaly) and spinal (spina bifida)
NTDs as well as neural crest and limb muscle defects (21).
We found that folate deficiency results in an increased fre-
quency of cranial NTDs in embryos carrying the Sp2H
mutation, and we investigated the possible mechanisms by
which this effect is mediated.
RESULTS
Folate deficiency increases the incidence of NTDs
in splotch mutants but not wild-type embryos
In order to investigate the relationship between folate status
and genetic susceptibility to NTDs, we induced dietary
folate deficiency in heterozygous female splotch (Sp2H) mice
prior to mating to generate experimental litters. Mice were
maintained for a minimum of 4 weeks on a synthetic folate-
free diet (designated FD), which included antibiotic to
remove gut bacteria that synthesize folates. This strategy fol-
lowed that of Burgoon et al. (15), except that mice were not
housed on grids to prevent coprophagy. Quantification of red
cell folate confirmed that, compared with the standard breed-
ing diet (SD), there was a significant reduction in whole
blood folate concentration in dams maintained on the FD
diet (Fig. 1A). This correlated with an increase in plasma
Figure 1. Embryonic folate content shows only partial correlation with
maternal blood folate and homocysteine (Hcy) concentration. Whole blood
folate (A; n ¼ 10–17) and plasma homocysteine (B; n ¼ 4–6) were quantified
in Sp2H/þ dams after maintenance for at least 6 weeks on the appropriate diet.
Embryonic folate content (C; n ¼ 10–14; Sp2H genotypes pooled) was
measured in stage-matched embryos at E10.5 (26–32 somite stage; mean
number of somites equal for each treatment). Values are given as mean+
SEM. Maternal blood folate and embryonic folate content were significantly
lower on all diets compared with the standard breeding diet (P , 0.001,
P, 0.05, compared with SD). Embryonic folate content was significantly
higher in the FD þ DF and FD þ BF diet groups than in the folate-deficient
group (†P , 0.001, compared with FD). Maternal homocysteine was
elevated in both the FD and FD þ BF groups compared with SD and FD þ
DF (#P , 0.001). SD, standard breeding diet; FD, folate-deficient diet;
FD þ DF, folate-deficient but with dietary folate available; FD þ BF, folate-
deficient but with bacterial folate available.
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homocysteine (Fig. 1B), validating the model and confirming
previous findings of an inverse correlation between folate
and homocysteine concentrations in humans and animal
models (9,15). To verify that maternal dietary folate
deficiency can affect the embryo, folate content of individual
embryos was quantified at E10.5. As expected, the total
folate content was lower in embryos of the folate-deficient
group compared with those on the SD (Fig. 1C).
Mice maintained under differing dietary folate regimes were
mated to generate embryos, which were analysed for fre-
quency of NTDs. Among wild-type embryos that developed
under either standard or folate-deficient conditions, NTDs
were never observed, in agreement with previous studies of
non-mutant mouse strains (14,15). In contrast, there was a
significant increase in the incidence of the cranial NTD, exen-
cephaly, among homozygous Sp2H offspring of mice main-
tained on the folate-deficient compared with SD (88 versus
61%; P, 0.05; Fig. 2A). Moreover, among heterozygous
Sp2H embryos, that do not develop NTDs under normal
dietary conditions, 10% displayed exencephaly. Spina bifida
occurs in more than 90% of Sp2H/Sp2H embryos developing
on a normal diet, so any increased risk would be difficult to
detect. However, we did not detect spina bifida among wild-
type or Sp2H/þ embryos developing under folate-deficient con-
ditions. Sensitivity to folate level does not appear to result
from diminished maternal uptake of folate by splotch dams,
as blood folate concentrations did not differ significantly
from a non-mutant strain (CD1), comparing mice either
under standard or folate-deficient conditions (Supplementary
Material, Fig. S1). Thus, we observe a gene–environment
interaction such that folate deficiency induces exencephaly
in genetically predisposed embryos carrying the Sp2H allele,
a proportion of which would have completed cranial neurula-
tion under folate-replete conditions.
Embryonic folate levels correlate with NTD incidence
In order to further confirm that the observed increase in
NTD incidence in Sp2H/Sp2H embryos was caused by folate
deficiency, we tested the effect of two control diets. The
first was identical to FD (including succinyl sulfathiazole anti-
biotic [SST]) but with the addition of dietary folic acid at
2.7 mg/kg, identical to the standard breeding diet. This diet,
designated FD þ DF (folate-deficient plus dietary folate) pro-
vided dietary but not bacterial folate. Both folic acid and SST
antibiotic were omitted from the second diet, allowing access
to bacterial folate but not to dietary folate. This diet was desig-
nated FD þ BF (folate-deficient plus bacterial folate).
Inclusion of dietary folic acid (FD þ DF) or removal of
antibiotic (FD þ BF) completely reversed the effect of the
folate-deficient diet, such that the NTD frequency did not
differ significantly from the standard dietary conditions
(Fig. 2A). However, when we quantified maternal blood
folate, mice fed on the FD þ DF or FD þ BF diets displayed
a relatively small increase in blood folate concentration com-
pared with FD (statistically significant only for FD þ DF).
Folate concentration remained significantly lower in these
dams, than in mice maintained on the SD (Fig. 1A). Avail-
ability of dietary or bacterial folic acid did affect plasma
homocysteine, resulting in significantly lower levels than in
Figure 2. Frequency of cranial NTDs among Sp2H/Sp2H embryos varies with
folate status. (A) Among Sp2H/Sp2H embryos that developed under folate-
deficient (FD, n ¼ 33) conditions, a significantly higher incidence of exen-
cephaly (at E10.5–11.5) was observed than among embryos developing
under conditions of standard diet (SD, n ¼ 34); # indicates significant differ-
ence compared with SD (P , 0.05, Fisher exact test). In contrast, incidence of
exencephaly under conditions of folate deficiency but with dietary folate avail-
able (FD þ DF, n ¼ 12) or folate deficiency but with bacterial folate available
(FD þ BF, n ¼ 14) did not differ from the SD (P. 0.05). Maternal sup-
plementation with folic acid reduced the incidence of exencephaly among
both SD embryos (SD þ FA, n ¼ 24) and FD embryos (FD þ FA, n ¼ 23),
although this effect reached statistical significance only for the FD þ FA
group (indicates significant difference compared with FD, P , 0.01, Fisher
exact test). Thymidine treatment (FD þ Thy, n ¼ 7) did not reduce the fre-
quency of exencephaly. (B) The sex of a subset of embryos was determined
(indicated as M or F above bar). On the SD the frequency of exencephaly
was higher among females (F, n ¼ 7) than males (M, n ¼ 11), and remained
higher after folic acid treatment (SD þ FA; n ¼ 14 males, 11 females),
although these sex differences were not statistically significant. Under folate-
deficient (FD) conditions both sexes exhibited a high frequency of exence-
phaly (n ¼ 19 males, n ¼ 9 females). However, while folic acid significantly
reduced the frequency of exencephaly among males (n ¼ 17, indicates sig-
nificant difference compared with FD, P , 0.01, Fisher exact test), females
were almost completely resistant to folic acid (n ¼ 14) such that the frequency
of exencephaly was significantly higher among folic acid-treated FD females
than males (indicates significant difference compared with FD þ FA males,
P , 0.02).
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severe folate deficiency (Fig. 1B). Most strikingly, despite the
minimal effect on maternal blood folate concentration,
embryonic folate content was significantly higher in embryos
developing under conditions where either dietary (FD þ DF)
or bacterial folate (FD þ BF) were available, compared with
neither (FD) (Fig. 1C). Thus, available folate may be preferen-
tially taken up by the embryo, allowing the embryo to
‘amplify’ a small increase in maternal folate into a larger
increase in embryonic folate. These data demonstrate that
removal of both dietary folic acid and gut bacterial-derived
folate is necessary to generate significant folate deficiency,
and to enhance a genetic predisposition to NTDs.
We next tested the ability of exogenous folic acid to prevent
folate deficiency-induced NTDs, by administering folic acid to
pregnant dams prior to and during the stage of cranial neurula-
tion. This in vivo folic acid treatment reduced the frequency of
exencephaly in Sp2H/Sp2H embryos developing under normal
dietary conditions, as previously observed (22,23), and also
in folate-deficient embryos (Fig. 2A). The magnitude of
decrease in NTD frequency was greater in the FD than the
SD group, despite the difference in maternal ‘baseline’
folate status. Perhaps the folate deficiency-induced NTDs are
more amenable to prevention than NTDs which occur under
folate-replete conditions. Moreover, around one-third of
cranial NTDs are not prevented by folic acid in either treat-
ment group. The lower rate of NTDs in folate-treated groups
is unlikely to result from folic acid-induced lethality of
affected embryos as the number of implantation and resorption
rates did not differ between diets or treatment groups (Sup-
plementary Material, Table S1).
Folic acid treatment of folate-deficient dams (FD þ FA)
elevates maternal blood folate to 0.28+ 0.03 mg/ml (n ¼ 4),
a level which is intermediate between normal and folate-
deficient conditions (0.43+ 0.02 and 0.15+ 0.01 mg/ml,
respectively, as was shown in Fig. 1A). In the offspring
of these FD þ FA mice, embryonic folate content was
restored to apparently normal levels, 5.41+ 0.5 ng/embryo
in FD þ FA group (n ¼ 9) compared with 5.14+ 0.3 ng/
embryo (n ¼ 6) in SD group at the 22–26 somite stage
(note that for SD embryos at this stage the values are lower
than for SD embryos at the later, 26–32, somite stage
shown in Fig. 1C). Hence, the effect of exogenous folic acid
treatment in increasing embryonic folate concentration corre-
lates well with its ability to prevent a significant proportion
of the cranial NTDs seen in folate-deficient dams.
Female embryos are thought to be more susceptible than
males to cranial NTDs since there is a preponderance of
female embryos among anencephalic human fetuses (24) and
exencephaly is more frequent among female than male
embryos in several mouse strains (25,26). Therefore, we deter-
mined the sex of a subset of Sp2H/Sp2H embryos that devel-
oped under SD and FD conditions, both with and without
folic acid treatment. Under standard dietary conditions, the
incidence of exencephaly was higher among female than
male embryos (Fig. 2B), although this difference did not
reach statistical significance. Folic acid reduced the incidence
of NTDs by a similar magnitude in both sexes. Under folate-
deficient conditions exencephaly occurred at similarly high
frequency in male and female embryos (Fig. 2B). However,
there was a remarkable difference between sexes in the
efficacy of folic acid treatment, such that folic acid produced a
significant reduction in the frequency of exencephaly among
male embryos, but had almost no effect on females (Fig. 2B).
The effect of folate deficiency is not mediated through
excess homocysteine
Elevated homocysteine concentration in maternal blood is a
risk factor for human NTDs (5) and was found to occur in
association with reduced maternal and embryonic folate in
our dietary models (Fig. 1). A prevalent idea is that homo-
cysteine itself may cause NTDs (13,27). Arguing against this
hypothesis, we and others found that direct exposure of
mouse or rat embryos to excess homocysteine is toxic but
does not result in isolated NTDs (28,29).
The previous experimental studies were performed in non-
mutant strains and since we also find no effect of folate
deficiency in wild-type embryos, we reasoned that elevated
homocysteine might cause an increased rate of NTDs only
among ‘at risk’ Sp2H/Sp2H and Sp2H/þ embryos, analogous
to the effect of folate deficiency. In order to test this idea
directly, we exposed cultured splotch embryos to exogenous
homocysteine throughout a period of 40 h from E8.5, which
encompasses the entire period of cranial neurulation. As pre-
viously reported in CD1 mice (28), homocysteine concen-
trations of 500 mM and above resulted in significant
embryotoxicity (data not shown), whereas 250 mM homo-
cysteine was well-tolerated by cultured embryos. Thus, in
comparison to vehicle-treated controls, there was no apparent
effect of 250 mM homocysteine on embryo viability, growth or
developmental progression as indicated by yolk sac circulation
score, crown-rump length or somite number after culture,
respectively (Table 1). Moreover, exposure to homocysteine
had no apparent effect on cranial neurulation, as the rate of
exencephaly among homozygous mutant embryos was not
increased compared with vehicle-treated controls. No neurula-
tion defects were observed in heterozygous or wild-type
embryos (Table 1), in agreement with reported in vivo
studies (30). Similarly, spinal neural tube closure was not
delayed by homocysteine exposure, as indicated by compar-
able posterior neuropore lengths in treated and control
embryos of equivalent genotype (Table 1).
Folate concentration limits embryonic growth
and developmental progression
In addition to variation in the frequency of NTDs, maternal
diet had a striking effect on embryonic growth and develop-
mental progression, as indicated by crown-rump length and
somite number, respectively. For example, embryos develop-
ing in folate-deficient dams had a significantly smaller crown-
rump length and fewer somites than embryos developing
under other dietary conditions (Fig. 3), an effect that was irre-
spective of embryonic genotype (Supplementary Material,
Table S2). Developmental delay appeared to become progres-
sively worse as development proceeded, such that folate-
deficient embryos had on average 5.3 fewer somites
than normal at E10.5 and 6.6 fewer somites at E11.5
(Fig. 3A). Thus, assuming that embryos typically gain one
somite approximately every 2 h during neurulation stages, a
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folate-deficient embryo would take 10–13 h longer to reach a
specific somite stage, than controls.
As another measure of embryonic growth, we compared
protein content with somite number for individual embryos
developing under standard or folate-deficient conditions. At
a given somite number (used as a measure of developmental
stage) there was no apparent difference in protein content
between dietary groups, although the folate-deficient
embryos were older in gestational age (Fig. 4). Thus, folate
deficiency appears to perturb the relationship between
growth/developmental progression and gestational age, but
does not dissociate embryonic growth from developmental
progression.
We investigated in further detail the changing folate status
of embryos as they progressed through development, under
either standard or folate-deficient conditions. The total folate
content of embryos on the SD increased linearly with somite
stage, whereas folate-deficient embryos exhibited an unchan-
ging folate content from 15 to 40 somites (i.e. over a 50-h
developmental period; Fig. 5A). However, after normalization
to total embryonic protein content, folate concentration was
found to decrease with increasing somite number in both
control and folate-deficient embryos. Prior to the 20 somite
stage, folate concentrations for SD and FD embryos were non-
overlapping (Fig. 5B). Strikingly, at later stages, the data over-
lapped and there was no significant difference in the rate of
decline of folate concentration in embryos on the standard
and folate-deficient diets (Fig. 5B). We conclude, therefore,
that folate concentration is maintained with strict limits in
the embryo, suggesting a controlling effect of folate content
on embryonic growth.
Normalization of NTD incidence in the FD þ DF and
FD þ BF control diets correlated with enhanced embryonic
growth and development compared with the FD diet
(Fig. 3). The protective effect of folic acid cannot, however,
be entirely attributed to correction of overall growth retar-
dation. Intraperitoneal injection of folic acid into folate-
deficient dams significantly reduced the frequency of cranial
NTDs (Fig. 2A) and yet had no detectable effect on overall
embryonic growth and development at E11.5, despite the
significant reduction in NTD rate (Fig. 3). To further analyse
the possible role of overall embryonic growth in rescue of
NTDs, a further set of folate-deficient mice were treated with
thymidine. This treatment led to a significant improvement of
growth parameters (Fig. 3), but did not diminish the number
of Sp2H/Sp2H embryos with cranial NTDs (Fig. 2A).
However, only very small open regions of cranial neural tube
were present in the thymidine-treated embryos (compare
Fig. 6C and D), suggesting that the closure process was
enhanced, although ultimately failed to be completed.
Folate deficiency influences abundance of methylation
cycle intermediates
Folate metabolism is inter-linked with the methylation cycle
by the remethylation of homocysteine to methionine. We
showed previously that suppression of the methylation cycle
leads to cranial NTDs in mouse embryos (31,32). We hypo-
thesized that a less severe effect of folate deficiency on the
methylation cycle might also contribute to development of
NTDs in genetically susceptible embryos. Therefore, the
key methylation cycle intermediates s-adenosylmethionine
(SAM) and s-adenosylhomocysteine (SAH) were quantified
in folate-deficient embryos, and in somite-matched and gesta-
tional age-matched controls. In embryos developing under
control conditions, we observed a reduction in SAM/SAH
ratio with development from E10.5 to E11.5 (Table 2), as
found in previous studies (33).
Comparison of folate-deficient and control dietary groups
showed that, for gestationally matched embryos at E11.5,
there were small but non-significant differences in both
SAM and SAH concentrations, and in SAM/SAH ratio
(Table 2). In contrast, comparison of folate-deficient
embryos at E11.5 with somite-matched E10.5 controls
showed a significant elevation of SAH levels, resulting in a
significantly lower SAM/SAH ratio (Table 2). Hence,
SAM/SAH ratio in folate-deficient embryos is consistent with
gestational age but abnormally low for developmental stage
(as indicated by somite number). Comparison of splotch geno-
types did not reveal any significant difference in SAM or SAH
levels between genotypes (Supplementary Material, Fig. S2).
Supplementation of folate-deficient embryos with exo-
genous folic acid did not significantly alter SAM or SAH
abundance, or SAM/SAH ratio, compared with untreated FD
Table 1. Development, growth and incidence of NTDs among splotch embryos cultured in the presence of 250 mM homocysteine (Hcy)
Treatment/genotype No. Cranial NTDs PNP length (mm) Somites Crown-rump length (mm) Yolk sac score
Control
þ/þ 2 0 0.49+0.09 25.0+0.0 3.33+0.17 2.5+0.5
Sp2H/þ 10 0 0.42+0.12 25.7+0.78 3.37+0.13 2.4+0.3
Sp2H/Sp2H 5 2 (40%) 1.54+0.15 24.6+0.51 3.47+0.14 1.6+0.4
Hcy
þ/þ 4 0 0.18+0.09 23.0+1.9 3.19+0.30 1.3+0.3
Sp2H/þ 12 0 0.19+0.05 25.4+0.6 3.44+0.10 2.1+0.2
Sp2H/Sp2H 8 2 (25%) 1.32+0.19 25.0+0.7 3.6+0.20 2.0+0.3
Embryos were cultured for 40 h from E8.5, and no difference was observed between treatment groups in number of somites, crown-rump length
(indicators of developmental progression and growth respectively) or yolk sac circulation score (indicator of viability). As expected the PNP is
significantly enlarged in Sp2H/Sp2H embryos compared with other genotypes (P , 0.05; one-way ANOVA), but no difference was observed between
treatments for any genotype. The frequency of cranial NTDs among Sp2H/Sp2H embryos was not affected by homocysteine treatment (P . 0.05; Fisher
exact test).
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embryos. In contrast, thymidine treatment resulted in a
significant reduction in SAM/SAH ratio primarily owing to
increased SAH abundance (Table 2).
DNA methylation
The observed reduction of SAM/SAH ratio in folate-deficient
embryos could indicate reduced methylation potential. In
order to detect an effect of folate deficiency on overall DNA
methylation, we measured the ratio of methylated to unmethy-
lated cytosine in genomic DNA extracted from stage-matched
(28–29 somite) SD and FD embryos. Interestingly, despite the
difference in SAM/SAH ratio at this stage (Table 2), there was
no apparent effect of folate deficiency on methylation of total
genomic DNA (Table 3). As a positive control, non-mutant
CD1 embryos were cultured in the presence of the methylation
cycle inhibitor, ethionine, at a concentration known to cause
cranial NTDs (31). Following 24-h culture, from E8.5 to
E9.5, genomic DNA methylation was significantly reduced
in embryos exposed to ethionine, compared with control cul-
tured embryos (Table 3). Hence, there is no evidence for a
detrimental effect of folate deficiency on methylation capacity
in neurulation-stage mouse embryos.
DISCUSSION
Dietary factors have long been thought to play a role in deter-
mining susceptibility to NTDs, and attention has particularly
focused on folic acid-related molecules. Previous studies in
mice showed that dietary folate deficiency is insufficient to
induce NTDs in non-mutant strains (14,15). Similarly, we
found that folate deficiency did not cause NTDs in wild-type
embryos from splotch litters, despite depletion of maternal
blood and embryonic folate and an elevated circulating homo-
cysteine concentration. In contrast, induction of folate
deficiency in splotch (Sp2H) mutant embryos resulted in a sig-
nificant increase in cranial NTD frequency, indicating a gene–
environment interaction between loss of Pax3 function and
folate status. Notably, the effect of folate deficiency appears
more deleterious in female embryos than males, since
defects were not prevented by treatment with exogenous
folic acid. Increased female susceptibility to cranial NTDs is
also observed among human fetuses and other mouse strains
(24–26), but the mechanism remains unresolved. We are not
aware of published data suggesting an increased proportion
of females among apparently folic acid-resistant NTDs (i.e.
those cases where NTDs occurred despite folic acid sup-
plementation), but this area deserves further attention.
Previously, induction of folate deficiency in a different
splotch allele, Sp, was reported to have no effect on the inci-
dence of NTDs (34), although, in another study of Sp, NTDs
Figure 3. Developmental stage and size of embryos after development under
varying levels of folate. Splotch embryos (genotypes pooled) developing under
folate-deficient (FD) conditions had fewer somites (A) and smaller crown-
rump length (B) at E10.5 than embryos in all other dietary groups (significant
difference compared with other groups, P , 0.001, One-way ANOVA). At
E11.5, FD embryos still had significantly fewer somites and smaller crown-
rump length than embryos from the SD (P , 0.001). This difference was
not rescued by folic acid treatment (FD þ FA; P, 0.001 compared with
SD). In contrast, thymidine treatment (FDþTHY) resulted in normalization
of somite number in folate-deficient embryos (P . 0.05 compared with SD),
although FD þ THY embryos still had reduced crown-rump length
(P , 0.001 compared with SD). Values are given as mean+SEM.
Numbers of embryos at E10.5: 46 SD; 93 FD; 34 FD þ DF; 21 FD þ BF;
24 FDþTHY. At E11.5: 19 SD; 49 FD; 28 FD þ FA; 21 FDþTHY. See
Figure 1 for dietary group abbreviations.
Figure 4. Relationship between embryonic growth (protein content per
embryo) and developmental stage (somite number) in splotch embryos devel-
oping under differing dietary folate conditions. Black circles indicate standard
diet (SD), white circles indicate folate-deficient diet (FD). All splotch geno-
types were pooled for analysis. Note the exponential increase in protein
content with somite stage, with no differences between SD and FD dietary
groups. Hence, embryonic growth and developmental progression are not dis-
sociated in folate deficiency.
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could be prevented by folic acid and 5-methyltetrahydrofolate
supplementation (23). In the present work, both folate
deficiency and folate supplementation were found to affect
the frequency of NTDs in splotch mice carrying the Sp2H
allele. Although both Sp and Sp2H are thought to be effectively
null alleles (35), the frequency of cranial NTDs differs mark-
edly. For example, Li et al. (34) found exencephaly in only
around 8% of Sp/Sp embryos, whereas we observed this
NTD in 60% of Sp2H/Sp2H embryos. In contrast, spina
bifida is almost fully penetrant in both Sp (96%) and Sp2H
(90%) alleles. The frequency of exencephaly, but not spina
bifida, can be predictably altered by variation in the location
of Closure 2, the site of onset of cranial neural tube closure
(36). Although this closure event occurs most commonly at
the forebrain–midbrain boundary, some genetic backgrounds
exhibit Closure 2 more caudally, in the midbrain, and these
strains are resistant to exencephaly. Conversely, strains with
Closure 2 at a more rostral location, within the forebrain,
are predisposed to exencephaly. It remains to be determined
whether this genetic background difference can explain the
differing propensities of existing mouse colonies carrying
the Sp and Sp2H alleles to develop cranial NTDs.
Another factor that may explain the apparent variation in
response to folate deficiency of Sp and Sp2H mice is the differ-
ing methodology used to deplete folate in the two studies. Our
analysis of maternal blood folate demonstrated that both
dietary and bacterial sources of folate must be removed to
achieve profound folate deficiency and an elevated homo-
cysteine concentration. In fact, some previous studies have
shown further reduction in folate status by maintaining dams
on grids to prevent coprophagy, another source of folate
(15). The study of Sp mice (34) used diets containing
reduced amounts, but not complete absence, of folic acid. In
the present study, the FD þ BF or FD þ DF diets, in which
bacterial or dietary folate was still available, resulted in a
smaller reduction in embryonic folate content than when
both dietary and bacterial folate were removed, and did not
increase the frequency of cranial NTDs, similar to the obser-
vations of Li et al. (34).
How does folate deficiency predispose to NTDs? Folate
one-carbon metabolism plays several key cellular roles includ-
ing provision of nucleotides for DNA synthesis and generation
of SAM, the methyl donor in cellular methylation reactions.
We found that lack of folates caused a profound retardation
of embryonic growth and developmental progression,
suggesting that cell proliferation is compromised. Thus, at a
given gestational age, folate-deficient embryos contained less
protein, and had smaller crown-rump length and fewer
somites, than embryos developing under folate-replete con-
ditions. Strikingly, analysis of individual embryos showed
that folate concentration at a specific developmental stage
(as defined by somite number) does not differ between con-
ditions where folate is deficient or replete. Neither is there a
dissociation of embryonic growth and developmental pro-
gression. These findings suggest that embryonic folate avail-
ability places an absolute limit on the rate of growth and
developmental progression. Cranial neural tube closure
appears particularly susceptible to factors that suppress pro-
liferation (26), and we speculate that the developmental
delay imposed by folate deficiency may exacerbate the under-
lying defect in splotch mutant embryos, thereby increasing
risk of NTDs. In particular, the observed developmental
delay implies that the period of neural tube closure is longer
in folate-deficient embryos, perhaps increasing vulnerability
to factors, such as loss of Pax3 function, that inhibit closure.
Although treatment of folate-deficient litters with exogenous
folic acid did not ameliorate overall developmental delay or
growth retardation, there was a significant preventive effect
on cranial NTDs. We speculate that exogenous folic acid
may cause a localized stimulation of proliferation in the
cranial neural folds that opposes the cellular defects imposed
by loss of Pax3 function, thereby enhancing closure and
diminishing NTD risk.
In addition to growth retardation, folate deficiency also
caused a significant decrease in SAM/SAH ratio, compared
Figure 5. Developmental change in embryonic folate status. Folate and
protein content were measured for a series of splotch embryos (genotypes
pooled for analysis) at different developmental stages (as indicated by
somite number). Each data point represents an individual embryo. Embryonic
folate content (A) increases with developmental stage for embryos developing
under standard dietary conditions (SD, solid line), whereas there is no discern-
ible increase for embryos developing under folate-deficient (FD, dashed line)
conditions. Linear regression lines were fitted (FD, solid line, r2 ¼ 0.700; SD,
dashed line, r2 ¼ 0.024) and show significant difference in gradient between
dietary groups (P , 0.001, t-test). In contrast, folate concentration (B), nor-
malized to protein content, declines with development. Prior to 20 somites
the rate of decline is greater in FD than SD embryos, but after the 20
somite stage there is no apparent difference between SD and FD groups.
Thus, at a given somite stage the protein concentration of FD embryos is
the same as for SD embryos, although the embryo is gestationally older.
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with somite-matched controls, suggesting that the methylation
cycle might be suppressed. Indeed, inhibition of the methyl-
ation cycle is known to induce a high frequency of cranial
NTDs in cultured mouse embryos and in chick embryos
(31,32,37). On the other hand, global DNA methylation was
not affected in our folate-deficient embryos, in contrast to
embryos exposed to the methylation cycle inhibitor, ethionine,
which showed significant inhibition of global DNA methyl-
ation. Currently, we cannot rule out the possibility that folate
deficiency specifically suppresses methylation of certain criti-
cal DNA sequences. For example, adult mice or rats maintained
on folate-deficient diets exhibit hypomethylation at the p53
locus (38,39), although effects on the developing embryo
have not been reported. Cell culture models also suggest that
low folate status may affect expression of other genes involved
in cell cycle regulation (40). It is also possible that methylation
of other macromolecules, such as proteins or RNA, may be
compromised. Nevertheless, taken together, we currently find
no evidence to indicate that folate deficiency exacerbates
NTDs in predisposed splotch embryos via inhibition of cellular
methylation.
How might our findings relate to the causation of human
NTDs? Clinical trials have shown a clear protective effect of
folic acid supplementation, but the link between maternal
dietary folate and risk of human NTDs is not well-understood
(13). One of the difficulties of assessing risk factors for human
Figure 6. NTDs in splotch embryos Neural tube closure is completed among all wild-type embryos (SD embryo shown in A), whereas Sp2H/Sp2H embryos
(B–D) exhibit NTDs, comprising spina bifida (arrowhead in B and D) and/or exencephaly (C and D, region of open neural folds is indicated by arrows). In
FD conditions, the region of open neural folds encompasses the midbrain or mid- and hindbrain (C), whereas thymidine-treated embryos exhibit a small
region of open neural folds (D).
Table 2. Abundance of methylation cycle intermediates is affected by folate-deficient diet
Diet/treatment Gest. age No. No. somites SAM (nmol/mg protein) SAH (nmol/mg protein) Ratio SAM/SAH
SD E10.5 40 29.8+0.3 3.35+0.26 0.024+0.002 147+7
SD E11.5 14 40.1+0.6 3.28+0.29 0.033+0.004 111+18
FD E11.5 18 29.6+0.9 2.94+0.23 0.050+0.011 96+12
FD þ FA E11.5 29 28.7+0.7 3.29+0.35 0.041+0.005 97+14
FD þ THY E11.5 13 35.5+0.3 3.58+0.20 0.063+0.004 59+4#
SAM and SAH were quantified in individual splotch embryos from different dietary groups (genotypes pooled). Owing to the developmental retardation
of folate-deficient (FD) embryos, both somite-matched (E10.5) and gestational age-matched (E11.5) control embryos (SD) were analysed. SAH
abundance increases and SAM/SAH ratio decreases with stage, under normal dietary conditions ( significant difference compared with E10.5 SD,
P , 0.015). In folate-deficient embryos, SAH abundance is elevated and SAM/SAH ratio decreased compared with somite-matched controls
( compared with E10.5 SD, P , 0.002), whereas SAM, SAH and SAM/SAH ratio do not differ significantly from gestation age-matched controls
(compared with E11.5 SD, P. 0.05). Folic acid treatment does not significantly alter SAM and SAH abundance compared with FD alone. Thymidine
treatment of FD embryos results in a significant decrease in SAM/SAH ratio (# indicates significant difference from FD, P , 0.002).
Table 3. Genomic DNA methylation in the embryo is apparently unaffected by folate-deficient diet
Diet/treatment Gest. age No No. somites Methyl Cyt/total Cyt (%)
SD E10.5 (early) 5 28.2+0.4 2.76+0.24
FD E10.5 (late) 9 28.4+0.2 2.75+0.15
Cultured embryos
Control E9.5 2 pools 19.5+0.3 3.26+0.13
Ethionine E9.5 2 pools 19.2+0.7 1.80+0.02
The ratio of 5-methylcytosine to total cytosine was measured in genomic DNA from somite-matched splotch embryos that developed in vivo under
differing dietary conditions (no significant difference). No differences were apparent between genotypes and data has been pooled in the table. As a
control experiment, non-mutant CD1 embryos were cultured for 24 h, from E8.5 to 9.5, with 5 mM ethionine (an inhibitor of the methylation cycle). As
predicted, DNA methylation was reduced in ethionine-treated embryos (n ¼ 5) compared with controls (n ¼ 4), and three out of five ethionine-treated
CD1 embryos exhibited cranial NTDs.
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NTDs is the inaccessibility of the neurulation-stage human
embryo for biochemical analysis. In most cases, the folate
status of the embryo has been inferred from maternal folate
concentrations, sometimes measured at much later stages of
pregnancy. In the present study, measurement of embryonic
folate concentrations showed that removal of either dietary
or gut bacterial folate sources had only minimal effects on
embryonic folate, and did not increase NTD frequency,
whereas maternal blood folate was markedly depleted under
such dietary conditions. Thus, embryonic folate content, but
not maternal blood folate, correlates with NTD risk in Sp2H
mice. These findings do not support a model based purely
on maternal folate status, and emphasize the need for
caution in interpreting human data based on relatively small
changes in maternal blood folate concentrations. On the
other hand, our data provide considerable support for the
idea that genetic factors, in addition to folate status, are critical
in determining risk of NTDs. The complex aetiology of human
NTDs certainly provides scope for the majority of cases to
involve multiple interacting factors, both genetic and environ-
mental. For example, the pattern of recurrence of human
NTDs favours a polygenic or oligogenic inheritance model,
rather than dominant or recessive single-gene inheritance
(6). Moreover, mouse studies suggest that many different
genes have the potential to play a role, perhaps in numerous
combinations (6).
Recently, using fibroblastic cell lines derived from human
fetuses with NTDs, we found that a subset of NTDs are associ-
ated with abnormal folate metabolism (41). It could be envi-
saged that reduced folate availability would further enhance
such a defect, increasing NTD risk. In addition, the apparent
effects of folate deficiency on embryonic growth and develop-
ment suggest that depletion of embryonic folate could also
exacerbate more general cellular risk factors for NTDs.
A goal for the future, therefore, is to identify the genetic
variants that are responsible for abnormal cellular folate
metabolism in a proportion of human fetuses with NTDs,
and to determine the mechanisms by which such genetic pre-
disposition can be exacerbated by embryonic folate deficiency,
and ameliorated by folic acid supplementation.
MATERIALS AND METHODS
Maintenance of mice, dietary conditions
and collection of embryos
Sp2H mice were maintained as a random-bred colony, and
genotyped by PCR using primers to Pax3 (21). Mice were rou-
tinely fed a standard breeding diet (Harlan Teklad) containing
2.7 mg/kg folic acid. For dietary studies, female mice were
randomly allocated at 6 weeks of age to the SD or to one of
three synthetic protein-based diets (TD.04083, TD.04297
and TD.04296) that were matched to the SD for micronutrient
levels, with the exception of folic acid. No folic acid was
present in diets FD and FD þ BF, while 1% succinyl sul-
fathiazole (10 g/kg) was included in diets FD and FD þ DF.
Females were maintained on each diet for a minimum of 4
weeks before mating to males which had been fed the standard
breeding diet.
Experimental litters were generated by overnight matings
between heterozygous mice, the day of finding a copulation
plug being designated embryonic day 0.5 (E0.5). In vivo sup-
plementation was by intraperitoneal injection, daily from E7.5
to 10.5, using 1 mg/ml folic acid (Sigma) in sterile phosphate
buffered saline (PBS), to a dose of 10 mg/kg, or 0.1 mg/ml
thymidine (Sigma) in PBS, to a dose of 1 mg/kg. Mice were
killed by cervical dislocation and embryos were dissected
from the uterus in Dulbecco’s Modified Eagle’s medium (Invi-
trogen) containing 10% fetal calf serum. Embryos were rinsed
in PBS and immediately frozen on dry ice for biochemical
analysis or fixed in 4% paraformaldehyde for other studies.
Genotyping of embryos
Genotyping was performed by PCR using DNA extracted from
yolk sacs. Splotch genotype was determined using primers to
Pax3 (21) and embryonic sex was determined using sex-
specific primers to amplify the Smcx and Smcy genes (42).
Quantification of folate and homocysteine
in maternal blood
Mice were anaesthetized with halothane and blood was col-
lected by cardiac puncture and immediately transferred to
lithium–heparin-coated tubes (MicrotainerTM, BD). Whole
blood folate was measured using the L. Casei microbiological
method (43). A second aliquot was centrifuged and plasma
was stored at 2708C prior to quantification of homocysteine
by standard methods (44).
Quantification of folate in embryo samples
Embryonic folate was measured using an adapted version of
the L. Casei microbiological method (43). Briefly, each
embryo was sonicated in water, on ice, to produce a homo-
geneous solution. An aliquot was taken for determination of
protein concentration using the bicinchoninic acid protein
assay reagent (Pierce, Rockford, IL). To include measurement
of both mono- and polyglutamylfolates (total folate), the
sample was incubated with conjugase extract (partially puri-
fied rat serum) in a 1% ascorbic acid buffer for 60 min at
378C to convert polyglutamylfolates to assayable monogluta-
mylfolates and then diluted within the range of the standard
curve with 0.5% sodium ascorbate.
Quantification of SAM and SAH
Samples consisting of a pool of 2–4 embryos from a specific
treatment group were analysed in duplicate by liquid chromato-
graphy coupled to electrospray ionization tandem mass spec-
trometry (LC-ESI-MS/MS) as described previously (33).
DNA methylation assay
Splotch embryos developing under folate-deficient (n ¼ 9) or
standard conditions (n ¼ 5) were collected at the 28–29
somite stage. CD1 mouse embryos were cultured for 24 h
from E8.5 to E9.5 in the presence of 5 mM ethionine or PBS
(control group), as described previously (31). Genomic DNA
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was prepared from individual splotch embryos and from pools
of three CD1 embryos following culture (n ¼ 6 embryos for
each treatment), using a QIAamp DNA mini kit (Qiagen).
DNA was hydrolyzed by formic acid and analysed by
LC-ESI-MS/MS, as described previously (45).
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Supplementary Material is available at HMG Online.
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